Phase II Study of the Oral MEK Inhibitor Selumetinib in Advanced Acute Myelogenous Leukemia: A University of Chicago Phase II Consortium Trial
暂无分享，去创建一个
Scott E. Smith | R. Larson | W. Stock | K. Shannon | A. Doyle | W. Stadler | T. Karrison | N. Jain | H. Erba | M. Kirschbaum | E. Curran | P. Dy | O. Odenike | L. Joseph | N. Iyengar | L. Popplewell | E. Atallah | X. Poiré | P. Reddy | Margaret Green | R. Kunnavakkam | E. Diaz-Flores | G. Koval | Sachdev Thomas